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Abstract
Acetaminophen is a widespread and commonly used painkiller all over the
world. However, it can cause liver damage when taken in large doses or at
repeated chronic doses. Current models of acetaminophen metabolism are
complex, and limited to numerical investigation though provide results that
represent clinical investigation well. We derive a mathematical model based
on mass action laws aimed at capturing the main dynamics of acetaminophen
metabolism, in particular the contrast between normal and overdose cases,
whilst remaining simple enough for detailed mathematical analysis that can
identify key parameters and quantify their role in liver toxicity. We use sin-
gular perturbation analysis to separate the different timescales describing
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the sequence of events in acetaminophen metabolism, systematically identi-
fying which parameters dominate during each of the successive stages. Using
this approach we determined, in terms of the model parameters, the critical
dose between safe and overdose cases, timescales for exhaustion and regener-
ation of important cofactors for acetaminophen metabolism and total toxin
accumulation as a fraction of initial dose.
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1. Introduction1
Acetaminophen (paracetamol; APAP N-acetyl p-aminophenol) is a com-2
monly used pain killer and antipyretic. It is an easy to obtain medication3
that is nowadays widely stocked in pharmacies and corner shops, in packets4
of up to 32 tablets (16 in Europe); enough to cause serious liver damage5
if ingested in a single dose. It is estimated that in the U.S. an average of6
56000 people are admitted to the hospital each year due to acetaminophen7
overdoses and their related effects. Over 450 people a year go on to die8
from acetaminophen overdose. In the U.S. alone, adverse drug reactions are9
ranked as being between the 4th and 6th leading cause of death [1]. Worry-10
ingly, around a quarter of these deaths are not from an intentional overdose11
by way of a suicide attempt, but from chronic use of the drug. The number of12
deaths associated with acetaminophen overdose in the U.S. almost doubled13
over a 4 year period, from 98 deaths in 1997 to 173 deaths in 2001 [2]. In the14
UK, 90 to 155 people died per year between 2000 and 2008 with additional15
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deaths due to acetaminophen being taken with other drugs [3]. This ease16
of availability and lack of awareness of its potential hazards means that ac-17
etaminophen is responsible for 80% of drug-associated cases of liver injury [4],18
and drug-induced liver injury has become the most common cause of acute19
liver failure and subsequently transplantation in Western countries [5]. Much20
of our understanding of the metabolism and toxicology of APAP comes from21
animal models, particularly rat and mouse. Interestingly there is consider-22
able variation in toxicity between species [6].23
APAP is taken orally and is absorbed into the blood stream. It arrives in24
the liver via the hepatic portal vein and moves through the liver mass to the25
central vein (Figure 1). In this time, APAP is absorbed into the hepatocytes26
where it is metabolised. In the liver, hepatocyte function is determined by27
position relative to the portal vein, with functions differing if a hepatocyte is28
near the blood inlet (periportal) or outlet (centrilobular), an affect known as29
zonation and is present across all areas of the liver [7]. APAP is metabolised30
in the liver primarily by the sulphation and glucuronidation pathways [8, 9],31
while around 5% is metabolised, via oxidation, to form the toxic metabolite32
N-acetyl p-benzoquinone imine (NAPQI) [10]. A detailed pathway diagram is33
shown in Figure 2 and a simplified one used as the basis for the mathematical34
modelling is shown in Figure 3. The sulphation pathway involves the conju-35
gation of APAP with the cosubstrate 3’-phosphoadenosine 5’-phosphosulfate36
or PAPS. This cosubstrate is finite within the liver cell and at toxic doses we37
see PAPS levels fall [11] and a saturation of the sulphation pathway, leading38
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to higher metabolism through glucuronidation and oxidation. The cofactors39
associated with the glucuronidation pathway have a much higher capacity40
than those of the sulphation pathway [12] and we assumed in our modelling41
that the pathway does not saturate at clinically relevant, high APAP doses.42
Via the oxidation pathway, APAP is catalysed by select enzymes from a ‘su-43
perfamily’ of enzymes known as Cytochrome P450 [13]. The main enzymes44
involved in this reaction in human cells are Cytochromes CYP2E1,CYP3A445
and CYP1A2 [13, 14, 15], however, the sub-type and hence nomenclature of46
the enzymes varies by species when looking at animal models. Metabolism47
through oxidation produces NAPQI, a chemically reactive and toxic metabo-48
lite. NAPQI can be detoxified by GSH, an antioxidant which conjugates to49
NAPQI preventing binding with essential proteins and thus preventing dam-50
age to the liver. At sufficiently high doses, the sulphation cosubstrate, PAPS,51
can be exhausted, diverting quantitatively more APAP through the oxida-52
tion pathway, leading to higher amounts of NAPQI being produced. There53
are marked species differences in the sensitivity to APAP, e.g. rats are re-54
sistant to equivalent doses of APAP compared with humans, and this is due55
to a much greater capacity for sulphation and a lowered propensity for ox-56
idation [16]. Oxidation has the effect of depleting GSH levels in the liver,57
through binding with NAPQI and hence greater levels of protein adducts58
are produced. GSH can also be depleted by individual factors such as alco-59
holism [17] and anorexia [18] though this inter-patient variability is beyond60
the scope of the mathematical model to be presented in this paper.61
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Figure 1: Structure of the liver [36]. Blood flows from the portal field (left) to the
central vein. APAP in the blood diffuses into the hepatocytes and is metabolised.
It is broadly recognised that mathematical modelling now plays a signifi-62
cant part in the drug development process. A successful model provides a cost63
effective way of understanding and predicting drug efficacy and toxicology,64
thus offering a systematic means of guiding more focused, less exploratory,65
use of animal models. Despite acetaminophen being the subject of labora-66
tory studies for many years, it is only recently that theoretical studies on67
the toxicology of paracetamol have been undertaken. One of the first math-68
ematical models produced is by Reith et al. [12], who focused on examining69
the kinetics of the glucuronidation and sulphation pathways using a 14 vari-70
able ordinary differential equation (ODE) model and fitting to human data,71
specifically excreted products in the plasma. Ochoa et al. [19] took a mul-72
tiscale approach, combining a detailed cell based APAP metabolism model,73
comprised of 34 variables, with a whole body model to simulate actions in74
the liver and transport between organs. Both these models are rich in detail75
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Figure 2: A diagram of the cell scale metabolic network for APAP metabolism.
The abbreviations are: APAP, acetaminophen; UGTs, UDP-glucuronosyltransferases;
SULTs, sulfotransferase; NQO1, NADPH-quinoreductase; CYPs, cytochrome P450;
APAP-G, acetaminophen glucuronide; APAP-S, acetaminophen sulphate; NAPQI, N-
acetyl-p-benzoquinone imine; GSTs, glutathione S-transferase; GSH, glutathione; APAP-
GSH, acetaminophen glutathione conjugate. Subscript ’B’ denotes non-specific binding to
a protein or lipid. Subscript ’P’ denotes binding to non-specific protein [19]. Blue boxes
are non specifically bound products, yellow boxes are molecules, white boxes are isozymes,
red boxes are protein bound molecules and green boxes are further metabolic systems not
described in this diagram.
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Figure 3: Pathway Diagram for APAP Metabolism. APAP is metabolised through
3 main pathways, sulphation, glucuronidation and oxidation. CYP oxidation creates
NAPQI, a harmful metabolite which can bind with essential cellular proteins within the
hepatocytes if no GSH is present. Modelled species are APAP (P), NAPQI (N), PAPS
(S), GSH (G) and Drug-Protein Adducts (C).
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and parameter estimation, but their complexity prohibits investigation using76
more advanced mathematical techniques. Multi-compartmental models have77
also been tested by Ben-Shachar et al. [20] who looked to create a model78
that would reproduce clinical and experimental data on APAP and metabo-79
lite levels in the plasma and urine. They looked to reproduce the data of80
Prescott et al. [21] examining APAP metabolism in human patients. Again,81
this model is complex and so it is difficult to apply mathematical analysis.82
Remien et al. [22] investigate a simple model for APAP metabolism, utilis-83
ing a tissue-scale model to predict biomarker levels, which can be used to84
estimate overdose amount, time elapsed since overdose, and likelihood of pa-85
tient survival. In this paper we will present a cell-based model that describes86
the major pathways in the system, which is more detailed then the model87
proposed by Remien et. al but very much simpler than that of Reith and88
Ochoa et al. [12, 19]. This model will in fact be applicable to a broad range89
of drugs that are metabolised in the liver via (1) a non exhaustible pathway90
(i.e. glucuronidation), (2) an exhaustible pathway (i.e. sulphation) and (3)91
an oxidation pathway that leads to GSH binding and toxic conjugate for-92
mation. The resulting model is amenable to two forms of analysis. Firstly,93
to identify which parameters have the most affect on the predicted outcome94
through sensitivity analysis and, secondly, to derive relatively simple for-95
mula, using singular perturbation analysis, for factors such as critical initial96
dose and timescales for peak toxic activity. This will enable us to probe the97
model to gain great insight in to how individual mechanisms in the model98
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can affect and influence these factors. Though the focus will be on APAP99
metabolism in humans, the modelling and analysis is applicable preclinical100
animal models also.101
We seek to create a model that captures the most important aspects102
of APAP metabolism and toxicity at the cellular level. We then analyse103
the model both numerically and analytically in order to develop a better104
understanding of the interactions in the modelled system. We also wish to105
identify any data gaps which can then be pursued experimentally. In the106
next section we will derive the model. In Section 3.1 we present simulations,107
showing the metabolic responses to bolus doses of APAP and undertake108
parameter sensitivity analysis. In Section 4 we perform a detailed timescale109
analysis, to derive formula characterising APAP metabolism. Finally we110
summarise the key results and discuss future work in Section 5.111
2. Mathematical Modelling112
Model Background.113
We focus on the metabolism of paracetamol within a single hepatocyte,114
aiming to capture the main dynamics of APAP metabolism while maintaining115
enough simplicity that analytical progress is possible. The full metabolic116
process is summarised in Figure 2 and, as stated before, broadly separates117
into three pathways. Describing all of the pathways illustrated in Figure 2118
would lead to an extremely complex model involving 20+ state variables and119
many more parameters. Instead, as a first approximation, we bundle all the120
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pathways in the glucuronidation route into a single pathway and likewise121
for sulphation and oxidation. The reduced pathway diagram used for the122
model is shown in Figure 3. We assume for sulphation and glucuronidation123
that the first reaction down each pathway is non-, or negligibly, reversible, so124
that events downstream do not directly affect paracetamol metabolism. For125
the oxidation pathway, we assume a single generic CYP is involved which126
represents the combined actions of CYP2E1, CYP3A4 and CYP1A2.127
Model Description.128
We use mass action laws to derive a system of ordinary differential equa-129
tions that describe the dynamics over time of the different pathways illus-130
trated in Figure 3. The resulting model is the same as that presented, but not131
studied, in Williams et al. [23], we will nevertheless outline the model deriva-132
tion. The model variables are listed in Table 1 and we note they represent133
quantities per cell.
Table 1: Model variables and their units.
Variable Interpretation Units
P Paracetamol (APAP) mol/cell
S Sulphate (PAPS) mol/cell
N NAPQI mol/cell
G GSH mol/cell
C Protein Adducts mol/cell
134
Our model assumes an initial bolus dose being delivered. The metabolism135
depends on the size of the initial dose. At regular doses the majority of APAP136
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will be metabolised by the sulphation and glucuronidation pathways [10].137
APAP (P ) undergoes sulphation by reacting with the PAPS enzyme (S) at138
rate kSSP , where kS is the rate constant associated with the metabolism139
of APAP by PAPS, ultimately forming APAP-S. In humans, PAPS is ex-140
haustible and so at high doses may, in some situations, see a saturation of141
the pathway. We define the rate constant for the production of PAPS by the142
liver as bS and the rate constant for the natural decay as dS. In contrast,143
we assume that the enzymes involved in glucuronidation are not exhaustible144
and are present at an approximately constant concentration, hence APAP145
metabolism along this pathway is in affect a natural decay at rate kGP .146
The remaining APAP is metabolised via the oxidation pathway creat-147
ing NAPQI (N). We assume that cytochrome P450 enzymes are present148
continuously at an approximately fixed concentration, so that the oxidative149
pathway is described as a further “natural decay” term, k450P . This reaction150
is assumed reversible at rate kNN .151
NAPQI is assumed to be metabolised via one of two pathways. The first152
is by reaction with the antioxidant GSH (G) at a rate kGSHNG. At normal153
doses of APAP we expect to see nearly all of the NAPQI produced being154
detoxified by this pathway. Conjugation with GSH renders NAPQI harmless155
and it is excreted from the body with no ill effects. In our model GSH is156
assumed to be constitutively produced at a constant rate bG and naturally de-157
cays at rate dGG. In fact, the production and regulation of GSH production158
is quite complex, being released from skeletal muscle [24] and regulated as an159
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adaptive mechanism by NRF2 [25]; at the level of detail of the current model160
we assume that constant bG is a reasonable starting point for modelling single161
doses. The second pathway has NAPQI creating drug-protein adducts (C)162
at a rate kPSHN . This binding to cellular macromolecules can result in cell163
death if the proteins that are bound are essential for cell function/viability.164
We do not consider the downstream events caused by drug-protein adducts165
and the variable C represents the total accumulated amount of a toxic re-166
action (we therefore hereon refer to C as toxins in that they are capable of167
inducing cell death).168
We arrive at the following model describing the pathways in Figure 3 and
including the stated assumptions;
dP
dt
= − kSSP − kGP − k450P + kNN, (1)
dS
dt
= − kSSP + bS − dSS, (2)
dN
dt
= k450P − kNN − kGSHNG− kPSHN, (3)
dG
dt
= − kGSHNG+ bG − dGG, (4)
dC
dt
= kPSHN. (5)
169
170
We assume in this study that the drug is introduced into cells as a single bolus171
dose at t = 0 at a concentration PS . The cells at this point are assumed to172
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be at pretreatment steady-state level. The initial conditions for this system173
are thus174
P (0) = PS , S(0) =
bS
dS
, G(0) =
bG
dG
, N0 = 0, C(0) = 0. (6)
Table 2 lists the model parameters and their estimated values for the175
standard simulation. Where possible, we obtained their values from the lit-176
erature and any remaining parameters through repeated simulation, so that177
the numerical results matched reasonably well with similar simulations from178
Remien et al. [22]. It is generally considered that anything more than 4g179
taken at once is considered an overdose, so we use 4g as our safe dose case [26]180
(though it is recommended to take no more than a 1g dose at 4 hour intervals).181
182
3. Results183
3.1. Simulation184
Our aim is to understand the effect of dose on both NAPQI produc-185
tion and timescales of events in APAP metabolism. We solve the system186
of equations (1) - (5) using the MATLAB routine ode15s, a variable order187
backwards difference method. Unless otherwise stated, we use the parameter188
values listed in Table 2.189
We first examine the single 4g dose case, i.e. a daily dose in a single190
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Table 2: List of model parameters and values used in standard simulation
Parameter Value Units Notes
P0 1.32× 10−13 mol· cell−1 See (1)
dG 2 day
−1 [27, 28, 29]
bG 1.374× 10−14 mol· cell−1· day−1 [22]
kGSH 1.6× 1018 cell·mol−1· day−1 [30]
kG 2.99 day
−1 [12]
k
[∗]
S 2.26× 1014 cell·mol−1· day−1 See (2)
b
[∗]
S 2.65× 10−14 mol· cell−1· day−1 See (2)
d
[∗]
S 2 day
−1 Equal to dG
k
[∗]
450 0.315 day
−1 See (3)
k
[∗]
N 0.0315 day
−1 See (4)
kPSH[∗] 110 day
−1 See (5)
(1) 4g dosage, standard single dose assuming 80% of dose reaches liver.
(2) Assuming initial PAPS is 10% of standard APAP dose i.e. bS
dS
= P0
10
, and
initially sulphation and glucuronidation are about the same, i.e. kS =
kGdS
bS
i.e. amounts to 47.5% of APAP processing initially.
(3) Equal to kG
9.5
i.e. we assumed only 5% of APAP is oxidised initially.
(4) Assumed kN =
k450
10
i.e. forward reaction is dominant.
(5) Assuming at normal GSH concentration, bG
dG
, only 1% of NAPQI binds
with the hepatocytes, i.e. kPSH = 0.01
kGSHbG
dG
.
Parameters marked with [∗] indicate parameters chosen by us to produce
physiologically realistic results.
bolus. We expect GSH levels to remain non-negligible to ensure a safe low-191
level conjugation of NAPQI. Consequently, protein adducts will then stay at192
very low levels. Both of these features can be observed from the simulation193
in Figure 4 (left column).194
It can be seen that neither GSH or Sulphation levels drop to zero, indi-195
cating that all APAP in the system is being dealt with effectively. We do196
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Figure 4: Plot of the evolution of, from top to bottom, APAP, PAPS, NAPQI,
GSH and protein adducts respectively. The units in each graph are mol/cell, noting
the two orders of magnitude difference between the levels in N and C. Here 4g (left) and
16g (right) correspond to P0 = 1.32× 10−13 and P0 = 5.28× 10−13 mol/cell, respectively.
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see a rise in NAPQI, however overall levels are extremely low relative to our197
overdose case and therefore do not pose any great risk. The same can be198
observed for the protein adducts, which remain at low levels compared to199
the overdose case.200
For the overdose case of 16g, a likely outcome is that both GSH and sul-201
phate levels will become exhausted at some stage of the metabolism process.202
This indeed occurs as can be seen in Figure 4 (right column). Sulphates drop203
very rapidly to a near zero level and take a long time to recover; this means204
that proportionally more APAP will be conjugated into NAPQI. This leads205
to a rapid drop in GSH to negligible levels that are sustained for a period206
of about 40 hours. This rise in NAPQI and subsequent depletion of GSH207
results in a high level of formation of protein adducts in comparison with our208
safe dose simulation. We note that a 4x increase in dose leads to an almost209
104× increase in accumulated protein adducts.210
Figure 5 shows the affect of the initial dose on the total amounts of toxic211
protein adducts produced, presented as C∞/PS , where C∞ represents the212
steady state level i.e. C → C∞ as t → ∞ and the ratio C∞/PS represents213
the fraction of adduct molecules produced per APAP molecule. At levels just214
slightly above a safe dose of 4g it can be seen that the amount of protein215
adducts in the system rises rapidly. This rapid increase in protein conjugate216
formation displays how dangerous overdoses involving APAP are. Small in-217
creases in the dose above what is considered “safe” lead to huge increases218
in the protein adducts being produced, which in turn can lead to extensive219
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damage to the liver. This threshold behaviour is due entirely to the level220
of GSH depletion of which leads to the fraction of protein adducts produced221
increasing 1000-fold over a 3-5g dose (we note that in Remien et al the lowest222
doses for patients receiving treatment is about 5g). The sensitivity of the223
model solutions to parameter change is explored in the next section, whilst224
the key parameters governing the threshold dose are established in the analy-225
sis of Section 4. We note that as PS →∞, the sulphation pathway becomes226
less significant and it follows that C∞/PS → k450/(kG + k450) ' 0.095 as227
PS →∞.228
Simulations investigating the effect of smaller regular doses are shown in229
Figure 6, in particular those in the left column represent a typically pre-230
scribed 1g dose at 4 separate 4 hour intervals over a 5 day period. Here, we231
observe NAPQI progressively building up in the initial days before settling232
to a periodic profile. Protein adducts increase linearly, although total levels233
still remain negligible.234
The right hand side of Figure 6 plots a higher than recommended chronic235
dose case, this time with the patient taking 1.5g of APAP every 4 hours. This236
increase in APAP leads to a rapid depletion of GSH resulting in NAPQI and237
conjugate levels two orders of magnitude higher than in the 1g case. NAPQI238
and protein adducts both rise rapidly (after a day) due to the lack of GSH in239
the system to safely deal with the NAPQI present. The plots once again show240
dramatic increase in toxic effects (represented by an increase in adducts, C)241
following a modest overdose.242
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Figure 5: Plot showing the effect of initial dose (P0) on final accumulated toxins
normalised as the ratio C∞/PS . The dashed line represents the value of P ∗0 which is
found in section 4.3.1. The stars represent the location of 4g and 16g doses.
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Figure 6: Plots showing evolution of pathways over time in response to a 1g per
dose (left) and 1.5g per dose (right) chronic APAP regimen.
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3.2. Parameter Sensitivity Analysis243
The results in Section 3.1 demonstrated a notable sensitivity to dose.244
In this section we seek to establish the sensitivity of the model solution to245
changes in parameter values. To do this systematically we used the Latin246
Hypercube method implemented using the “lhsdesign” routine in MATLAB.247
To produce the results that followed, the routine was set up to run 500 iter-248
ations, which randomly selects parameters between set limits of 3x and 1
3
x249
their original value. We used, for the sensitivity test, the total accumulated250
protein adducts C∞ (i.e. C(t) as t→∞), where we plotted this against each251
of the model parameters. We look for trends in the resulting graphs, indi-252
cating higher or lower numbers of protein adducts in response to a change253
in parameters. To confirm our observation we also examined the Sobol in-254
dices to estimate the sensitivity of variance of the model output, C, to the255
variance of the parameters [31]. Defining indices Si (the first order effect)256
and STi (the total effect index) to be the conditional expectation divided257
by the unconditional variance and the total output variation due to a given258
parameter respectively. Then STi −Si = 0 indicates that a parameter has no259
affect on the variance of the model output.260
Shown in Figure 7 are the results of the sensitivity analysis for the safe261
dose of 4g. We observe that most of the graphs do not show any sort of trend262
in response to differing parameter values except that the k450 (oxidation rate263
constant) graph shows an obvious upward trend in protein adducts whilst a264
downward trend is observed for kG (glucuronidation rate constant). Here,265
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the Sobol indices are found to be STkG − SkG ' 0.35, STk450 − Sk450 ' 0.32266
and STbG − SbG ' 0.2, while all other values are less than 0.05 confirming267
the visual analysis of the parameter sensitivity. Interestingly, the indicated268
sensitivity to bG is not present in the 16g case, suggesting that this is likely269
to be an important parameter when doses are near to the “critical level”.270
However, as the Sobol Indices for bG in the overdose case indicate that it has271
no significant affect on the model output, we do not feel that any further272
analysis is necessary for this parameter. The sensitivity analysis for the273
overdose case of 16g is shown in Figure 8. Again we see that changes in274
the value of k450 and kG produce the most distinct trends in the model. In275
the overdose case, STkG − SkG ' 0.16 and STk450 − Sk450 ' 0.06, while all276
other values are again less than 0.05. These are the only 2 parameters with277
a notable affect on the model outcome in the overdose regime.278
This analysis suggests that the key mechanisms that govern paracetamol279
metabolism are glucuronidation and oxidation, where increasing kG reduces280
toxicity and increasing k450 enhances it. In the parameter range investigated,281
PAPS contributes only up to about 10% of APAP metabolism, whereby282
sulphation is a secondary process in humans; we note that the sulphation for283
rats lies outside the parameter range investigated. Figures 9 and 10 show284
the dependence of the total toxins produced, C∞, on the two most sensitive285
parameters k450 and kG, for the safe and overdose cases. The results were286
generated from running the simulation to approximate C∞(t = 50), we found287
this length of time sufficient to reach a steady state. From Figure 9 we see288
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Figure 7: Final accumulated toxic levels from a 4g (‘safe’) dose against each of
the paramaters for 1000 iterations of randomly selected values between the
limits of 1/3x and 3x the nominal value listed in Table 2.
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Figure 8: Final accumulated toxic levels from a 16g overdose against each of the
paramaters for 1000 iterations of randomly selected values between the limits
of 1/3x and 3x the nominal value listed in Table 2.
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Figure 9: Total protein adduct formation against k450 for the safe (4g, dashed)
and overdose (16g, solid) cases. The dotted line indicates the standard value corre-
sponding to data in Table 2.
that increased k450 will lead to more APAP being oxidised instead of being289
metabolised by sulphation or glucuronidation. This will cause a rise in the290
amount of NAPQI in the system, putting more strain on the GSH pathway.291
We anticipate that a higher value for k450 will lead to more protein adducts292
being present in the system and therefore increase the risk of liver damage.293
The safe dose response shows a steady increase in conjugate levels ini-294
tially, followed by a rapid rise in conjugate levels being produced with total295
protein adduct formation increasing by over one order of magnitude. A296
less dramatic rise in protein conjugates is observed for higher k450 values.297
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For our overdose case we see a much faster rise in the total protein adduct298
formation in response to higher k450 levels. We see an increase of approxi-299
mately three orders of magnitude in response to higher values of k450. After300
the initial rapid increase in total protein adduct formation, higher values of301
k450 have a much lower affect on C∞. Once GSH is depleted in our sys-302
tem, all NAPQI that is oxidised will produce protein adducts, the rate at303
which these protein adducts can be formed is then dependent on how quickly304
NAPQI can be oxidised, this rate is k450. This suggests that after GSH is305
depleted fully, conjugate production will be proportional to k450. The rate of306
APAP to NAPQI metabolism can be affected by other factors such as caf-307
feine consumption [32, 33] and, for example, consumption of anti-convulsant308
drugs [34] which would result in a higher value of k450.309
In Figure 10 we observe, as expected, a decline in toxins produced as kG310
increases. As with k450, there is a fairly sharp transition between high and311
low toxicity at a certain value of kG. We note that a 10-fold increase in kG is312
required in the overdose case (kG ∼ 18 /day) to produce minimal toxic levels313
in comparison to the safe doses (kG ∼ 1.5/day). Furthermore, for kG ∼ 0314
/day there is a 10-fold difference in C∞ levels. This is due simply to more315
APAP being present for longer in the overdose case. The critical role of GSH316
exhaustion is highlighted in Figure 11, which plots the numerically predicted317
minimum value against parameters kG and k450. Of particular note is how318
the value of kG and k450 at which the sharp jumps occur correspond to jumps319
in Figure 9 and 10.320
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Figure 10: Total protein adduct formation vs. kG for the safe (4g, dashed) and
overdose (16g, solid) cases. The dotted line indicates the standard value of kG found
in Table 2.
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Figure 11 plots the minimum GSH levels in the cell against kG and k450.321
As kG increases we see a rise in the minimum GSH level of 2 orders of322
magnitude. This suggests that if the glucuorindation rate drops then GSH323
could fall low enough to allow protein adducts to form, if for example a person324
has a genetic or environmental deficiency e.g. co-medication, that reduces the325
amount of glucuornidation cofactor it could be dangerous for them to take326
paracetamol, even in safe doses. We observe in the overdose case that only327
very large values of kG have a non-negligible affect on minimum GSH levels.328
An increase in k450 leads to a drop in GSH of over 3 orders of magnitude in the329
safe dose case, at the normal value of k450 = 0.315 /day, minimum GSH levels330
remain high in the cell. However, an increase in k450 leads to lower GSH levels331
which could lead to the formation of protein adducts. Therefore, increased332
k450 can potentially lead to liver damage via protein adduct formation even333
in safe dose cases.334
3.3. Cellular dose variation335
The structure of the liver lobule means that cells closer to the portal vein336
are likely to receive more of the drug. As a a consequence, there will be a dis-337
tribution of drug dosage between cells in the liver. Some cells which receive338
higher doses are more likely to be damaged than others. Furthermore, dif-339
ferences in micro-environment due to proximity to blood vessels and oxygen340
gradients could also affect drug metabolism. The effects of the the micro-341
environment will be subject to a future publication, and here we investigate342
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Figure 11: Plot showing minimum GSH levels in the hepatocytes against kG
(left) and k450 (right). The dotted vertical lines indicate the original parameters values
from Table 2.
how the spread of drug dosing effects the probability of cell death given a343
dose.344
In Figure 12, we assume that a dose of paracetamol is log-normally dis-345
tributed between the hepatocytes in the liver. We assumed that a lethal dose346
for cells (pL) is 5 times the daily safe dose [22] and we plotted the probability347
p > pL, given a mean dose log(p¯s) and variance σ
2, against mean dose. We348
observe that higher standard deviations lead to a less sharp profile. It is349
expected that 70% total cell death will lead to the death of the patient [22],350
in our simulations we see that this occurs from ∼ 7 × 10−13 mol/cell (ap-351
prox. 5 times the standard dose) to ∼ 9 × 10−13 mol/cell (approx. 7 times352
the standard dose). Interestingly, we also see that greater variation between353
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Figure 12: Plot showing the fraction of cell death in response to an increasing
initial paracetamol dose, normally distributed amongst cells.
hepatocytes leads to more deaths at lower doses, but less death at higher354
doses. This suggests that variation is a positive property for the popula-355
tion on average, for survival against a very large, single dose. However, this356
doesn’t necessarily mean it is a positive property for the individual.357
4. Timescale Analysis358
In the previous section we were able to get some insight into how certain359
parameters effect the predicted toxicological outcome. In this section we will360
employ singular perturbation theory to get a much better analytical under-361
standing of APAP metabolism according to the model. Close examination362
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of Figure 4 reveals the existence of distinct timescales, starting with a rapid363
decline in PAPS and GSH followed by longer timescales for recovery. To ap-364
ply this theory we first non-dimensionalise the system of equations (1) - (5).365
Using the data values in Table 2, we express the new parameters in terms366
of a single small parameter  (i.e.   1), which will be exploited in the367
analysis. We will summarise the main results here, and we refer the reader368
to the supplemental material for full details.369
4.1. Non-dimensionalisation370
To aid the analysis we rescale our variables in order to eliminate units,
which allows comparison of variables and parameters in terms of their mag-
nitude, so that the dominant and negligible mechanisms can be systemati-
cally identified. Since glucuronidation is the dominant metabolism route for
APAP, we rescale time with parameter kG; using the value in Table 2, the
dimensionless time tˆ = 1 thus represents about 8 hours. We rescale PAPS
and GSH with their untreated levels and rescale APAP, NAPQI and protein
adducts to a reference value P0 which represents the liver cell level of a 4g
dose i.e. P0 = 1.32× 10−13 mol/cell. The rescalings are thus,
t =
1
kG
tˆ, P = P0pˆ, S =
bS
dS
sˆ, N = P0nˆ, G =
bG
dG
gˆ, C = P0cˆ.
and we note the standard dose concentration P0 corresponds to pˆ = 1. The
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dimensionless system of equations is then
dpˆ
dtˆ
= −αˆ∗S sˆpˆ− pˆ− pˆ+ 2kˆ∗N nˆ, (7)
dsˆ
dtˆ
= − αˆ
∗
Sφˆ
∗
S sˆpˆ

+ δˆ∗S(1− sˆ), (8)
dnˆ
dtˆ
= pˆ− 2kˆ∗N nˆ−
kˆ∗PSH

nˆ− αˆ
∗
G
3
nˆgˆ, (9)
dgˆ
dtˆ
= − αˆ
∗
Gφˆ
∗
G
4
nˆgˆ + δˆ∗G(1− gˆ), (10)
dcˆ
dtˆ
=
kˆ∗PSH

nˆ, (11)
where the rescaled parameters are listed in Table 3. The third column of
Table 3 lists the value of the parameter, and for the purpose of the analysis we
will rewrite them in terms of the small parameter  = k450/kG ' 0.1 guided by
magnitudes indicated in the 4th column; thus starred values in equations (7)-
(11) are defined as kˆN = 
2kˆ∗N , αˆS = αˆ
∗
S etc. These dimensionless variables
are subject to the initial conditions
pˆ(0) = PS , sˆ(0) = 1, nˆ(0) = 0, gˆ(0) = 1, cˆ(0) = 0,
recalling that PS = 1 represents the 4g dose case. Henceforth, we will drop371
the hats and the *’s for clarity. In Section 4.2 we provide an overview of372
the main mathematical results and we then give biological interpretations in373
Section 4.3374
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4.2. Application of singular perturbation theory375
The system (7)-(11) will be analysed in the limit  → 0. Using singular376
perturbation theory we can perform this analysis systematically and formally377
reduce the full system to a sequence of timescales in which the system reduces378
to a simpler solvable one in each timescale. This will enable us to identify379
when a particular process is important and determine an approximation to380
key quantities such as critical dose in terms of the model parameters. Full381
details of the analysis is given in the supplementary material and we present382
only the “highlights” below. A summary of this analysis and the important383
timescales and events is provided in Section 4.3. We note that toxic levels of384
protein adducts will be c = O(2) as shown in Figure 5.385
Table 3: Table of dimensionless parameters, their values and the assumed value
relative to the reference small parameter .
Parameter Definition Value Order in terms of 
kˆ450 k450/kG 0.105 
kˆN kN/kG 0.0105 O(2)
αˆS kSbS/dSkG 1 O(1)
φˆS P0dS/bS 10 O(1 )
δˆS dS/kG 0.668 O(1)
kˆPSH kPSH/kG 36.8 O(1 )
αˆG kGSHbG/dGkG 3680 O( 13 )
φˆG P0dG/bG 19.3 O(1 )
δˆG dG/kG 0.668 O(1)
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4.2.1. t = O(3)386
On introduction of the APAP bolus there is a rapid adjustment over
t = O(3), the first 30 seconds or so, in which NAPQI is produced at very
low levels. Denoting variables in this timescale with a superscript *, we write
t = 3τ ∗, p = p∗, s = s∗, n = 4n∗, g = g∗, c = 6c∗.
These rescalings are then substituted into our dimensionless equations (7)-
(11), subject to p∗ = PS , s∗ = 1, g∗ = 1, n∗ = 0 and c∗ = 0 at t∗ = 0. In each
timescale we seek solutions of the form
p(τ ∗) = p∗0(τ
∗) + p∗1(τ
∗) + 2p∗2(τ
∗) + ...
and likewise for the other variables. Substituting these expansions into our
equations we obtain to leading order p∗ ∼ PS , s∗ ∼ 1 and g∗ ∼ 1 (correction
terms can be found in our supplementary material) and
n∗ ∼ PS
αG
(1− e−αGτ∗),
c∗ ∼ kPSHPS (αGτ
∗ + e−αGτ
∗ − 1)
α2G
.
In this short initial timescale, APAP, PAPS and GSH remain relatively387
unchanged and NAPQI equilibrates to a negligible O(4) level. As t∗ → ∞,388
NAPQI settles to n ∼ 4 (PS /αG) and c ∼ 6 (kPSHPS τ ∗/αG). We note here389
that as τ ∗ →∞, n ∼ 4PS /αG, this represents the amount of NAPQI formed390
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if PAPS and GSH remain at their pretreatment levels. There is no change391
at leading order of p, s and g, however the correction terms become O(1) at392
τ ∗ = O(−2) i.e. at t = O().393
4.2.2. t = O()394
It is on this timescale at which sulphation is most prominent. We intro-
duce t = τ¯ and the relevant rescalings are
p = p¯, s = s¯, n = 4n¯, g = g¯, c = 4c¯.
Substituting the expansions above, p¯ ∼ p¯0 +p¯1 etc. into (7)-(11) and solving
leads to
p¯ ∼ PS + 
(
1
φS
(e−αSφSPS τ¯ − 1)− PS τ
)
,
s¯ ∼ e−αSφSPS τ¯ ,
g¯ ∼ 1 + (−φGPS τ¯),
n¯ ∼ PS
αG
,
c¯ ∼ kPSHPS
αG
τ¯ .
In this timescale, we see that sulphate levels drop rapidly whilst APAP is rela-395
tively steady. Biologically this is due to the conjugation of APAP and PAPS,396
leading to declining PAPS levels in the cell. The parameters used suggest397
that the pretreated PAPS concentration is O(PS ) so, at best, sulphates are398
34
only able to metabolise an O() fraction of the drug. There is also an increase399
in protein adducts, although they are still only present in very low amounts.400
We note as τ¯ → ∞, p¯ ∼ PS − 
(
φ−1S + PS τ¯
)
, where /φS represents the401
amount of APAP being metabolised by the sulphation pathway. There is a402
transition timescale t =  η1()+O(), where η1 = ln(1/)/αSφSPS , in which403
sulphate reaches a minimum constant level, namely s ∼ δS/αSφSPS ; sul-404
phation makes no further contribution to APAP metabolism at leading order.405
The expansion breaks down when τ¯ = O(1/), corresponding to t = O(1),406
when APAP concentration starts to significantly drop.407
408
4.2.3. t = O(1)409
In this timescale, we have two separate divergent cases. One in which
we have sufficient amounts of GSH in the system to conjugate NAPQI, the
other is characterised by a rapid drop in GSH and potential toxin build up.
The critical dose at which the two cases diverge is
P ∗S =
δ
δG
δG−1
G
φG
, (12)
such that, PS < P
∗
S can be classified as “safe” and PS > P
∗
S can be considered410
a potential overdose. We note here that we have assumed that δG 6= 1, we will411
omit details for the coincidental case of δG = 1 (i.e. δG = kG in dimensional412
terms).413
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In both cases, we adopt the following rescaling.
t = τ˜ , p = p˜, s = s˜, n = 4n˜, g = g˜, c = 3c˜.
Expanding these variables in the usual way, and solving the resulting system
yields
p˜ ∼ PS e−τ˜ − 
(
e−τ˜ (
δS
φS
− PS τ˜)− δS
φS
)
, (13)
s˜ ∼ δSe
τ˜
αSφSPS
, (14)
n˜ ∼ PS e
−τ˜
αG
(
φGPS
δG−1 (e
−δGτ˜ − e−τ˜ ) + 1
) = PS e−τ¯
αGΨ(τ¯)
, (15)
g˜ ∼ φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ) + 1 = Ψ(τ¯), (16)
c˜ ∼ kPSH
∫ τ˜
0
n˜(τ˜)dτ˜ . (17)
Here, APAP is metabolised such that p ∼ PS e−τ (due to glucuronidation414
at leading order) and that PAPS is recovering, noting that s = O() and415
therefore is not contributing to APAP metabolism at leading order. We also416
note that c˜ is unsolvable in this timescale, but we can deduce behaviour as417
τ˜ → τ˜ ∗ (see below), as explained in the supplementary material.418
The divergence depends on the function
Ψ(τ˜) = 1 +
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ), ∀τ˜ > 0
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whereby if Ψ(τ˜) > 0, ∀τ˜ > 0, then n˜ and g˜ remain positive and O(1), this419
is our safe dose case. If at τ˜ = τ˜ ∗, such that Ψ(τ˜ ∗) = 0, then n˜ → ∞ in420
finite time τ˜ → τ˜ ∗ whilst g˜ → 0. The divergence condition (PS = P ∗S) is421
determined by assuming that Ψ(τ˜ ∗) = 0 is a turning point at τ˜ = τ˜ ∗, i.e.422
solving Ψ(τ˜ ∗) = 0 and Ψ′(τ˜ ∗) = 0 simultaneously leading to t∗ = ln δ/(δ−1).423
We note that the safe and overdose cases can be connected smoothly by424
analysis in the region of PS = P
∗
S + θ, where θ ' O(1). The results are425
omitted as they are not of biological significance other than it reveals that426
the jump region observed in Figure 5 is of O() = O(k450/kG) in size.427
In the overdose case, when PS > P
∗
S , breakdown occurs when t ∼ µ1(),428
where µ1() is defined such that Ψ(µ1(0)) = 0; and g˜ = O() and n˜ = O(1/).429
Here, µ1() is the time at which hepatocytes no longer have an effective430
means of dealing with NAPQI. It is straightforward to show that µ1() is a431
decreasing function of PS and dg, i.e. more drug and less glutathione reduces432
the time interval, as expected. We further note that given Ψ(µ1) = 0 and433
Ψ′(µ1) < 0 we can show that φGPS e−µ1 > δG; this result is utilised in Section434
4.2.5. In the overdose case, breakdown occurs when t ∼ τ˜ ∗ = µ1(), where435
Ψ (µ1(0)) = 0 and Ψ(τ˜) = O(), so that g˜ = O() and n˜ = O(1/), this is436
discussed in Section 4.2.5.437
4.2.4. Safe dose case (PS < P
∗
S)438
Here, the drug decays exponentially (predominantly by glucuronidation)
and g˜ = O(1) throughout, i.e. GSH is able to handle the NAPQI being
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produced. Meanwhile sulphate cofactors are recovering but only at very low
levels. Protein adducts attain their maximum level i.e. O(3), namely
c∞ ∼ 3kPSHPS
αG
∫ ∞
0
e−τ
Ψ(τ)
dτ
There is a further timescale at t = ln(1/)+O(1) in which the sulphation439
factors, now O(1), continue to recover, and return to pre-treatment state.440
4.2.5. t = µ1() + O(1) (overdose).441
GSH and NAPQI continue to drop and rise, respectively, over a series of
intermediate timescales until the current one describing the time period at
which GSH is at its minimum level. We rescale our variables as follows
t = µ1 + τˇ , p = pˇ, s = sˇ, n = 
2nˇ, g = 2gˇ, c = cˇ.
We then expand our variables as before, substitute them into (7) - (11) and
solve to find
pˇ ∼ PS e(−µ1−τˇ),
sˇ ∼ δSe
µ1
αSφSPS
,
nˇ ∼ φGPS e
−µ1−τˇ − δG
kPSHφG
,
gˇ ∼ δGkPSH
αG(φGPS e−µ1−τˇ − δG) ,
cˇ ∼ PS e−µ1(1− e−τˇ )− δG
φG
τˇ
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In this timescale APAP levels continue to drop while sulphates remain steady.442
Protein adducts approach their maximum level while NAPQI production be-443
gins to slow and GSH levels begin to rise as APAP levels decline. The solu-444
tions in this timescale breakdown as τˇ → µ2()−, with µ2(0) = ln(φGPS /δG)−445
µ1(0), where gˇ = O(1/) and nˇ = O(). After this timescale, NAPQI levels446
begin to decline. As τˇ → µ−2 , c attains its maximum value to leading order,447
i.e. c∞ ∼ (PS e−µ1(1 − e−µ2) − µ2δG/φG). We can show that the amount448
of protein adducts increases with PS (i.e. higher initial dose) and φG (less449
GSH present) as would be expected.450
4.2.6. t = µ1() + µ2() + O(1) (overdose).451
This timescale follows a series of intermediate timescales in which GSH
rapidly recovers and NAPQI diminishes. Here, the rescalings are
t = µ1 + µ2 + τ
◦, p = p◦, s = s◦, n = 4n◦, g = g◦, c = c◦
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and proceeding as before
p◦ ∼ PS e−µ1−µ2−τ◦
s◦ ∼ δSe
µ1+µ2+τ◦
αSφSPS
n◦ ∼ PS e
−µ1−µ2−τ◦
αG(
φGPS e
−µ1−µ2
δG−1 (e
−δGτ◦ − e−τ◦) + 1)
g◦ ∼ φGPS e
−µ1−µ2
δG − 1 (e
−δGτ◦ − e−τ◦) + 1
c◦ ∼ PS e−µ1(1− e−µ2)− δG
kG
µ2
Here we see that APAP levels continue to drop exponentially, allowing PAPS452
levels to rise exponentially. GSH levels are now O(1) and will soon recover to453
its pretreated level, whilst the tiny amounts of NAPQI that remain rapidly454
decrease. We now have GSH returning to pretreated levels as NAPQI dimin-455
ishes.456
After this, the only timescale of significance is τ ◦ = ln(1/) + O(1),457
whereby p→ O() and s→ O(1), i.e. their pretreated levels.458
4.2.7. Comparison with numerics459
Figure 13 shows the evolution of the dimensionless APAP, PAPS and460
GSH concentrations against dimensionless time in an overdose case (left).461
As expected, the agreement improves as  decreases (right).462
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Figure 13: Plots of APAP, Sulphates, Drug-Protein Adducts and GSH against
dimensionless time in an overdose case, the left hand graph when  = 0.105
and the right hand graph when  = 0.1052. The horizontal dashed line shows our
analytical estimate for C∞, the vertical dashed lines show the estimates for GSH collapse
and recovery as discussed in section 4.3.4, 2.3.5 and 2.3.6.
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4.3. Timescale Analysis Summary463
Here we summarise the important events and timescales from the previ-464
ous section, expressing the key dimensionless quantities in their dimensional465
form.466
4.3.1. Critical paracetamol concentration467
In section 4.2.3, where t = O(1) we observe a divergence between our safe
and overdose cases. This divergence occurs at a critical concentration
P ∗S ∼
(
dG
kG
)kG/(dG−kG) bG
kG
, (18)
where P ∗S = 1.47×10−13mol/cell using the data available in Table 2. We note468
4g translates to a concentration of 1.32× 10−13 mol/cell and our divergence469
happens at a point 11% above this dose. This highlights the relatively low470
tolerance the liver has in response to large bolus doses of paracetamol.471
4.3.2. Exhaustion of sulphate472
Our analysis shows that sulphate is exhausted in the intermediate timescale
between 4.2.2 and 4.2.3. The approximate timescale for exhaustion of sul-
phate is
t ∼ k450
kGkSPS
ln(kG/k450),
which using the data is t ∼ 12 minutes for a 4g dose. After this point the473
pathway saturates and we a greater proportion of APAP being metabolised474
into NAPQI, impacting GSH levels. We note that the estimate is only log-475
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arithmically accurate and will not be as precise as those in Section 4.3.1,476
4.3.4 and 4.3.5 are; nevertheless it makes explicit how much faster PAPS is477
exhausted in response to an increased drug dose.478
4.3.3. Sulphate recovery479
In both safe and overdose cases, we see sulphate recover at t = ln(1/),
in dimensional parameters this is
t ∼ 1
kG
ln
(
kS PS kG
dS k450
)
.
Using the data this equates to about 40 hours after ingestion for a 4g dose;480
though we note, like that of Section 4.3.2, this estimate is only logarithmically481
accurate. Sulphate recovery is a long term process and the liver takes a long482
time to recover from a high paracetamol dose. In the case where a person483
uses paracetamol chronically to deal with pain then this long recovery time484
could impact how well the liver can deal with multiple doses. We note, as485
expected, that the recovery time is extended with dose, but in a sublinear486
fashion.487
4.3.4. GSH depletion488
In our overdose case, when PS > P
∗
S we observe a collapse in GSH levels
at t ∼ µ1 (Section 4.2.3). Where µ1 satisfies the implicit equation
1 +
kGdGPS
bG(dG − kG)
(
e−dGµ1 − e−kGµ1) = 0.
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This equation cannot be solved directly to find µ1 but given values of the489
parameters, the equation can be solved using the Newton-Raphson method.490
Using the data in Table 2 gives µ1 ≈ 0.046 for the overdose case, which using491
dimensionless parameters is µ1 ≈ 0.138 which is in good agreement with492
the numeric values shown in Figure 13. We then show that mathematically493
we can improve our estimate by reducing the size of . Similarly, we find494
t ∼ µ2 ≈ 2.358 in the overdose case, again providing good agreement with495
the numeric values shown in Figure 13. In terms of dimensional parameters496
this gives us µ2 ≈ 0.79, which is discussed further in section 4.3.5.497
4.3.5. GSH Recovery498
Again looking at the case where PS > P
∗
S , the time for GSH recovery is
given by
t ∼ 1
kG
ln
(
kGPS
bG
)
.
Which is approximately 8.9 hours for a 4g dose and 20 hours for a 16g dose.499
People regularly taking high doses of APAP can cause damage by not allowing500
time for GSH recovery and subsequently protein adduct formation could be501
high. Again, the plot in Figure 13 shows how this estimate of GSH recovery is502
accurate for our model and how smaller values of  (i.e. a decreasing k450/kG503
ratio) increase the accuracy of our estimate.504
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4.3.6. Total protein conjugate formation, C∞505
The total concentration of drug-protein adducts in in the overdose case,
PS > P
∗
S , is
C∞ ∼ k450PS e
−kgµ1
kG
− bGk450
k2G
(1 + kGµ2)
We note that the accumulated drug-protein adducts total is unaffected (to506
leading order) by parameters associated with PAPS. Moreover, we can show507
that C∞ increases with an increasing initial APAP dose and CYP reaction508
rate, and decreases in response to an increasing GSH production rate and509
glucuronidation reaction, as expected. Figure 13 shows that this offers a510
fair prediction of maximum drug-protein adduct levels. We note that no pa-511
rameters associated with sulphation have an affect on the final accumulation512
of protein conjugate formation and suggest that the sulphation pathway is513
unlikely to be a suitable target for an effective new treatment against the tox-514
icological effects of an APAP overdose. However, we should note that even515
though sulphates are “exhausted” by time t ∼ ln(kG/k450)/kGPS it is still516
removing APAP at around the same rate as the oxidative pathway between517
timescales 4-10 (see supplemental material).518
5. Discussion519
In this paper, we have derived a cell scale mathematical model which520
describes the metabolism of APAP in hepatocytes. In order to obtain insights521
into this system using analytical methods, we simplified the full metabolic522
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pathway to one that still maintains the three major pathways.523
The simulations demonstrated that the model captures the expected dy-524
namics of metabolism and, in particular, the distinguishing dynamics be-525
tween the safe and overdose cases. We observe the expected drops in both526
sulphate and GSH levels in the safe dose case and our overdose simulations527
have both pathways dropping rapidly to very low levels, which is what we528
expect from clinical observation. The results show that a 4x dose of APAP529
can lead to a 100-10000x increase in the amount of protein adducts being530
formed.531
Our sensitivity analysis has enabled us to identify the most sensitive pa-532
rameters in our model, we can use these to guide the research of biologists533
which will then provide further insight and help us to refine our model. The534
analysis in Section 3.2 showed that the key parameters are kG (the rate con-535
stant for glucuronidation) and k450 (the rate of oxidation); the other parame-536
ters have secondary effects on the dynamics and, in particular, the sulphation537
pathway is less influential than glucuronidation and oxidation. There is on-538
going work by the authors examining adaptive responses to chronic dosing.539
For example, if certain pathways become up-regulated in response to mild540
liver stress caused by APAP, then these sensitive parameters may be one of541
the contributing factors.542
It can be seen that system operates over a number of distinct timescales.543
At t = O() ∼ 45 minutes we see sulphate levels begin to decline in response544
to the APAP present. As time progresses, we observe that sulphates begin545
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to decline, and by t = O(1) ∼ 8 hours we see that sulphates have become546
exhausted as they drop by an order of magnitude (i.e. S = O()). At547
this stage in our analysis, we see a critical divergence between the safe dose548
and overdose cases at an initial paracetamol dose of 4.54g (using data from549
Table 2). We also are able to identify timescales for exhaustion and recovery550
of GSH and sulphates (details of which are available in the supplementary551
material). Of course there can be considerable individual variability that can552
affect the critical dose level. The sensitivity analysis has enabled us to deduce553
that changes in kG and k450 have the largest impact on the dynamics of the554
system. Further to this, the asymptotic analysis of Section 4 has allowed us555
to express key quantities (critical concentrations, timescales etc.) in terms556
of relatively simple formula (Section 4.3), so the effect of varying parameters557
can be explicitly observed. Such methods have broad application and are558
somewhat underused in the study of mathematical models in pharmacology.559
Our parameter selection is good but there are gaps in the current lit-560
erature that highlight a need for more data on the metabolism of APAP561
in humans. While literature is available which has allowed us to begin pa-562
rameterisation, further experimental work would benefit the robustness of563
the model greatly. The parameter values for glucuronidation and oxida-564
tion pathways are obtainable from the literature, whilst that of sulphation565
is less well characterised. Though the analysis in this paper suggests that566
acetaminophen metabolism via the sulphation pathway is secondary in hu-567
mans, it appears to be important in rats [12], which are much more resistant568
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to APAP at human toxic levels. Consequently the critical concentration ex-569
pression, equation (18), will be completely different for rats; we expect that570
the model is suitably generic to describe acetaminophen metabolism in other571
species with little modification. However, to fully understand the contrast572
between rat and human models, for example, more data on metabolism via.573
sulphation and subsequent model reparamaterisation for the different species574
is essential.575
Through numerical, sensitivity and asymptotic analysis we have improved576
our understanding of how the different pathways behave. We have high-577
lighted key parameters that our system is sensitive to and also found how578
the pathways interact with each other, and how this affects the production of579
protein adducts and the potential for toxicity. This work will provide a foun-580
dation on which to build by working directly with scientific researchers and581
provides us with new areas to research and expand upon using the existing582
model.583
This research is part of a larger project funded by the National Cen-584
tre for the Replacement, Refinement and Reduction of Animals in Research585
(NC3R’s) which aims to improve in vitro testing and reduce the animal test-586
ing in science [35]. From the initial results and insights, this model is an587
encouraging first step towards the long-term goal of combining modelling588
and experimental approaches to mitigate the use of animal testing in toxi-589
cological studies, for example, testing hypotheses which would normally be590
tested in animal models. It’s simplicity and analytical tractability means591
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that we can draw conclusions on key parameters that can then be found592
from in vitro data.593
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